| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.18 | 0.3 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | 0.13 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |